Effects of short-term chemical ablation of glucagon signalling by peptide-based glucagon receptor antagonists on insulin secretion and glucose homeostasis in mice

Biological Chemistry

Volumn 395, Issue 4, 2014, Pages 433-442

  Franklin, Zara J ^a   O'Harte, Finbarr P M ^a   Irwin, Nigel ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

antagonist; glucagon; glucose homeostasis; insulin secretion; mice

Indexed keywords

CHOLESTEROL; DESHISTIDYL 1 PROLYL 4 GLUTAMYL 9 GLUCAGON; GLUCAGON RECEPTOR; GLUCOSE; HORMONE ANTAGONIST; INSULIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; GLUCAGON; OLIGOPEPTIDE;

ABLATION THERAPY; ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN SENSITIVITY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; HOMEOSTASIS; INBRED MOUSE STRAIN; MALE; METABOLISM; SECRETION (PROCESS); STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; GLUCAGON; GLUCOSE; HOMEOSTASIS; INSULIN; MALE; MICE; MICE, INBRED STRAINS; OLIGOPEPTIDES; RECEPTORS, GLUCAGON; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84896748924     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/hsz-2013-0224     Document Type: Article

References (36)

1. Ahn, J.M., Medeiros, M., Trivedi, D., and Hruby, V.J. (2001). Development of potent glucagon antagonists: structure-activity relationship study of glycine at position 4. Pept. Res. 58, 151-158. (Pubitemid 32738418)
2. Ali, S., Lamont, B.J., Charron, M.J., and Drucker, D.J. (2011). Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis. J. Clin. Invest. 121, 1917-1929.
3. Bagger, J.I., Knop, F.K., Holst, J.J., and Vilsbøll, T. (2011). Glucagon antagonism as a potential therapeutic target in type 2 diabetes. Diabetes Obes. Metab. 13, 965-971.
4. Bromer, W.W., Sinn, L.G., Staub, A., and Behrens, O.K. (1957). The amino acid sequence of glucagon. Diabetes 6, 234-238.
5. Conarello, S.L., Jiang, G., Mu, J., Li, Z., Woods, J., Zycband, E., Ronan, J., Liu, F., Roy, R.S., Zhu, L., et al. (2007). Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia. Diabetologia 50, 142-50. (Pubitemid 46035862)
6. D'Alessio, D. (2011). The role of dysregulated glucagon secretion in type 2 diabetes. Diabetes Obes. Metab. 13, S1: 126-32.
7. Dunning, B.E. and Gerich, J.E. (2007). The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr. Rev. 28, 253-283. (Pubitemid 46984828)
8. Flatt, P.R. and Bailey, C.J. (1981). Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia 20, 573-577. (Pubitemid 11096955)
9. Gault, V.A., Irwin, N., Green, B.D., McCluskey, J.T., Greer, B., Bailey, C.J., Harriott, P., O'Harte, F.P., and Flatt, P.R. (2005). Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes. 54, 2436-2446. (Pubitemid 41134273)
10. Gelling, R.W., Du, X.Q., Dichmann, D.S., Romer, J., Huang, H., Cui, L., Obici, S., Tang, B., Holst, J.J., Fledelius, C., et al. (2003). Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. PNAS 100, 1438-1443. (Pubitemid 36184020)
11. Gu, W., Yan, H., Winters, K.A., Komorowski, R., Vonderfecht, S., Atangan, L., Sivits, G., Hill, D., Yang, J., Bi, V., et al. (2009). Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemia. J. Pharmacol. Exp. Ther. 331, 871-881.
12. Gu, W., Winters, K.A., Motani, A.S., Komorowski, R., Zhang, Y., Liu, Q., Wu, X., Rulifson, I.C., Sivits, G. Jr., Graham, M., et al. (2010). Glucagon receptor antagonist-mediated improvements in glycemic control are dependent on functional pancreatic GLP-1 receptor. Am. J. Physiol. Endocrinol. Metab. 299, E624-632.
13. Green, B.D., Irwin, N., Gault, V.A., Bailey, C.J., O'Harte, F.P., and Flatt, P.R. (2005). Chronic treatment with exendin(9-39)amide indicates a minor role for endogenous glucagon-like peptide-1 in metabolic abnormalities of obesity-related diabetes in ob/ob mice. J. Endocrinol. 18, 307-317. (Pubitemid 40691796)
14. Henquin, J.C., Accili, D., Ahrén, B., Boitard, C., Seino, S., and Cerasi, E. (2011). Long in the shade, glucagon re-occupies centre court. Diabetes Obes. Metab. 13, S1:v-viii.
15. Hruby, V.J. (1982). Structure-conformation-activity studies of glucagon and semi-synthetic glucagon analogs. Mol. Cell. Biochem. 44, 49-64. (Pubitemid 12087078)
16. Irwin, N., Gault, V.A., Green, B.D., Greer, B., McCluskey, J.T., Harriott, P., O'Harte, F.P., and Flatt, P.R. (2004). Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice. Biol. Chem. 385, 845-852. (Pubitemid 39335307)
17. Irwin, N., Clarke, G.C., Green, B.D., Greer, B., Harriott, P., Gault, V.A., O'Harte, F.P., and Flatt, P.R. (2006). Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide. Biochem. Pharmacol. 72, 719-728. (Pubitemid 44233552)
18. Irwin, N., McClean, P.L., Harriott, P., and Flatt, P.R. (2007). Beneficial effects of sub-chronic activation of glucagon-like peptide-1 (GLP-1) receptors on deterioration of glucose homeostasis and insulin secretion in aging mice. Exp Gerontol. 42, 296-300. (Pubitemid 46356848)
19. Irwin, N., Frizelle, P., Montgomery, I.A., Moffett, R.C., O'Harte, F.P., and Flatt, P.R. (2012). Beneficial effects of the novel cholecystokinin agonist (pGlu-Gln)-CCK-8 in mouse models of obesity/diabetes. Diabetologia 55, 2747-2758.
20. Irwin, N., Franklin, Z.J., and O'Harte, F.P. (2013). desHis(1) Glu(9)-glucagon-[mPEG] and desHis(1)Glu(9)(Lys(30) PAL)-glucagon: long-acting peptide-based PEGylated and acylated glucagon receptor antagonists with potential antidiabetic activity. Eur. J. Pharmacol. 709, 43-51.
21. Lau, J., Behrens, C., Sidelmann, U.G., Knudsen, L.B., Lundt, B., Sams, C., Ynddal, L., Brand, C.L., Pridal, L., Ling, A., et al. (2007). New beta-alanine derivatives are orally available glucagon receptor antagonists. J. Med. Chem. 50, 113-128. (Pubitemid 46105504)
22. Lee, Y., Wang, M.Y., Du, X.Q., Charron, M.J., and Unger, R.H. (2011) Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. Diabetes 60, 391-397.
23. Liang, Y., Osborne, M.C., Monia, B.P., Bhanot, S., Gaarde, W.A., Reed, C., She, P., Jetton, T.L., and Demarest, K.T. (2004). Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes 53, 410-417. (Pubitemid 38174557)
24. Mu, J., Jiang, G., Brady, E., Dallas-Yang, Q., Liu, F., Woods, J., Zycband, E., Wright, M., Li, Z., Lu, K., et al. (2011). Chronic treatment with a glucagon receptor antagonist lowers glucose and moderately raises circulating glucagon and glucagon-like peptide 1 without severe alpha cell hypertrophy in diet-induced obese mice. Diabetologia 54, 2381-2391.
25. Mu, J., Qureshi, S.A., Brady, E.J., Muise, E.S., Candelore, M.R., Jiang, G., Li, Z., Wu, M.S., Yang, X., Dallas-Yang, Q., et al. (2012). Anti-diabetic efficacy and impact on amino acid metabolism of GRA1, a novel small-molecule glucagon receptor antagonist. PLoS One 7, e49572.
26. O'Harte, F.P.M., Franklin, Z.J., Rafferty, E.P., and Irwin, N. (2013). Characterisation of structurally modified analogues of glucagon as potential glucagon receptor antagonists. Mol. Cell. Endocrinol. 381, 26-34.
27. Parker, J.C., Andrews, K.M., Allen, M.R., Stock, J.L., and McNeish, J.D. (2002). Glycemic control in mice with targeted disruption of the glucagon receptor gene. Biochem. Biophys. Res. Commun. 290, 839-843. (Pubitemid 34687519)
28. Sloop, K.W., Cao, J.X., Siesky, A.M., Zhang, H.Y., Bodenmiller, D.M., Cox, A.L., Jacobs, S.J., Moyers, J.S., Owens, R.A., Showalter, A.D., et al. (2004). Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J. Clin. Invest. 113, 1571-1581. (Pubitemid 39071680)
29. Sørensen, H., Winzell, M.S., Brand, C.L., Fosgerau, K., Gelling, R.W., Nishimura, E., and Ahren, B. (2006). Glucagon receptor knockout mice display increased insulin sensitivity and impaired beta-cell function. Diabetes 55, 3463-3469. (Pubitemid 44923606)
30. Triplitt, C.L. (2012). Examining the mechanisms of glucose regulation. Am. J. Manag. Care. 18, S4-10.
31. Unger, R.H. and Orci, L. (1975). The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet 1, 14-16.
32. Unger, R.H. and Orci, L. (1981). Glucagon and the A cell: physiology and pathophysiology (first two parts). N. Engl. J. Med. 304, 1518-1524. (Pubitemid 11065936)
33. Unson, C. G., Macdonald, D., Ray, K., Durrah, T.L., and Merrifield, R.B. (1991). Position 9 replacement analogs of glucagon uncouple biological activity and receptor binding. J. Biol. Chem. 266, 2763-2766. (Pubitemid 21909131)
34. Unson, C. G., Macdonald, D., and Merrifield, R.B. (1993). The role of histidine-1 in glucagon action. Arch. Biochem. Biophys. 300, 747-750. (Pubitemid 23232937)
35. Winzell, M.S., Brand, C.L., Wierup, N., Sidelmann, U.G., Sundler, F., Nishimura, E., and Ahrén, B. (2007). Glucagon receptor antagonism improves islet function in mice with insulin resistance induced by a high-fat diet. Diabetologia 50, 1453-1462. (Pubitemid 46879005)
36. Zhou, C., Dhall, D., Nissen, N.N., Chen, C.R., and Yu, R. (2009). Homozygous P86S mutation of the human glucagon receptor is associated with hyperglucagonemia, alpha cell hyperplasia, and islet cell tumor. Pancreas 38, 941-946.